CORRECTING and REPLACING Concentric Pharma Advertising Tapped to Advertise SOLESTA™ Upon Approval

NEW YORK--(BUSINESS WIRE)--Headline of the release dated September 9, 2010 should read: Concentric Pharma Advertising Tapped to Advertise SOLESTA™ Upon Approval (sted Concentric Pharma Advertising Tapped to Market SOLESTA™). Please also replace the release with the following corrected version due to multiple revisions.

“Their process-driven approach will uncover creative ways to communicate the benefits of this treatment to physicians treating, and patients dealing with, this overwhelming condition.”

The corrected release reads:

CONCENTRIC PHARMA ADVERTISING TAPPED TO ADVERTISE SOLESTA™ UPON APPROVAL

Agency to design online and offline campaigns for Oceana’s fecal incontinence device

Concentric Pharma Advertising, an independent healthcare advertising and marketing agency, announced today that the firm will be creating both online and offline campaigns for the launch of the fecal incontinence device SOLESTA™ from Oceana Therapeutics, Inc. SOLESTA™ is currently under review by the FDA.

According to the National Digestive Information Clearinghouse, more than 5.5 million Americans suffer from fecal incontinence. The condition can be caused by a variety of issues, including aging and childbirth, and treatments range from modifying nutritional intake to surgery. The condition can have significant effects on a patient’s quality of life and psychological well-being, as many people resort to altering their social and physical activities, even their employment, to cope with the problem.

“This is an exciting product because it provides a minimally invasive treatment that doctors can turn to when conservative therapies like increased fiber consumption and biofeedback don’t work, or when surgery isn’t an option,” said Mike Banner, EVP, Managing Partner & Director of Client Services with Concentric. “This can be as many as half of the patients suffering from fecal incontinence, who then have no other option but to learn to live with the problem.”

Concentric will create campaigns targeted to both the physician and consumer audiences across the print and online media.

“We have worked with Concentric on many projects over the past two years,” says Matthew Rue, Senior Vice President of Marketing for Oceana Therapeutics, Inc. “Their process-driven approach will uncover creative ways to communicate the benefits of this treatment to physicians treating, and patients dealing with, this overwhelming condition.”

About Concentric Pharma Advertising

Concentric is one of the country’s largest and fastest-growing independent healthcare advertising agencies. With expertise navigating the complexities of the specialty pharma environment, they deliver elegant, non-traditional promotional programs that impact market share.

From their offices in New York City and London, they serve a wide range of specialties including oncology, dermatology, neurology, urology, hepatology, and gastroenterology.

Their strength in digital media has led to groundbreaking programs like RepRace, a virtual sales force training platform. Concentric has been recognized with numerous industry awards and honors, most recently a Medical Marketing & Media Interactive Award and Pharmaceutical Executive Ad Stars.

For more information, visit www.concentric-rx.com.

About SOLESTA™

SOLESTA is approved for use in Europe and Canada as an injectable treatment for fecal incontinence. SOLESTA is a biocompatible substance composed of stabilized hyaluronic acid, including dextranomer, manufactured according to Q-Med AB’s patented technology, NASHA^TM. The treatment is a minimally invasive, in-office procedure. SOLESTA was developed in 2004 by Q-Med AB in Sweden. Oceana Therapeutics acquired the global rights to market and sell SOLESTA in June 2009.

About Oceana Therapeutics, Inc.

Oceana Therapeutics was founded in 2008 by a team of seasoned healthcare executives and is privately held. The Company is committed to acquiring and maximizing the potential of approved and late-stage development medical devices and specialty therapeutics, redefining the way illnesses are treated. Oceana’s goal is to enable physicians to prescribe drugs and utilize devices that are tailored for the patient’s disease—offering Optimal Outcomes—as well as the added economic benefit of limiting or eliminating hospitalization or reducing demand for surgery or emergency care. This approach balances both the patient’s wellness needs and the physician’s goal of providing outstanding patient care while efficiently balancing time and economic management constraints. For additional information about Oceana Therapeutics, visit the Company’s Web site at http://www.oceanatherapeutics.com.